Literature DB >> 31296634

A challenging diagnosis of MPO-C-ANCA EGPA.

Gareth Lim1, Sheryl Lim1, Shang-Ian Tee2, Chai Yiing Ling3.   

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic small-vessel vasculitic disease that can present with positive MPO-P-ANCA (myeloperoxidase-perinuclear-anti-neutrophil cytoplasmic antibody). It is a rare condition that is difficult to diagnose. We present the case of a 64-year-old man with late-onset adult asthma and treated nasopharyngeal carcinoma who initially presented to us with proximal myopathy. Thereafter, he developed a constellation of fleeting symptoms which included rhinosinusitis, mononeuritis multiplex, skin vasculitis and arthritis. Blood investigations showed that he had eosinophilia, and skin biopsy demonstrated dermal vasculitis with eosinophils. He was found to be MPO-C-ANCA positive, and although initially thought to have granulomatosis with polyangiitis, the diagnosis was later revised to EGPA. This case highlights the diagnostic challenges with atypical presentations of EGPA and also presents a rare case of positive MPO-C-ANCA that has never been described in EGPA before. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  rheumatology; vasculitis

Mesh:

Substances:

Year:  2019        PMID: 31296634      PMCID: PMC6626476          DOI: 10.1136/bcr-2018-228621

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.

Authors:  Renato A Sinico; Lucafrancesco Di Toma; Umberto Maggiore; Paolo Bottero; Antonella Radice; Cinzia Tosoni; Chiara Grasselli; Laura Pavone; Gina Gregorini; Stefano Monti; Micol Frassi; Filomena Vecchio; Caterina Corace; Emanuela Venegoni; Carlo Buzio
Journal:  Arthritis Rheum       Date:  2005-09

Review 2.  Small-vessel vasculitis.

Authors:  J C Jennette; R J Falk
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

3.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

Authors:  A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

4.  A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan.

Authors:  Ken-Ei Sada; Koichi Amano; Ritei Uehara; Masahiro Yamamura; Yoshihiro Arimura; Yoshikazu Nakamura; Hirofumi Makino
Journal:  Mod Rheumatol       Date:  2013-12-02       Impact factor: 3.023

5.  Some patients with anti-myeloperoxidase autoantibodies have a C-ANCA pattern.

Authors:  M Segelmark; B Baslund; J Wieslander
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

6.  Muscle weakness as a presenting symptom in ANCA-associated vasculitis.

Authors:  Hiroshi Oiwa; Takashi Kurashige
Journal:  Eur J Rheumatol       Date:  2017-11-02

7.  Myeloperoxidase-antineutrophil Cytoplasmic Antibodies with Cytoplasmic Fluorescence Pattern.

Authors:  Seema Chhabra; Ranjana Walker Minz; Lekha Goyal; Nidhi Sharma
Journal:  J Lab Physicians       Date:  2010-01

Review 8.  Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA - evidence-based immunology?

Authors:  Elena Csernok; Julia U Holle
Journal:  Auto Immun Highlights       Date:  2010-07-10

9.  MPO-C-ANCA-associated necrotising and crescentic glomerulonephritis.

Authors:  Abhilash Koratala; Dara N Wakefield; Kawther F Alquadan; A Ahsan Ejaz
Journal:  JRSM Open       Date:  2017-04-03

Review 10.  A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.

Authors:  Michele V Quan; Stephen K Frankel; Mehrnaz Maleki-Fischbach; Laren D Tan
Journal:  BMC Pulm Med       Date:  2018-11-29       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.